I Know I Shouldn’t Hate, but I Do
In the United States, cancer is the number one disease killer of children. Yet pediatric cancer isn’t exclusive to America; it’s a global epidemic that affects more than 300,000 children around the world.
Dr. Gregory Friedman’s Immunotherapy Research for Recurrent Brain Tumors Shows Promising Preliminary Results
As a Rally Researcher and the primary investigator at the University of Alabama at Birmingham, Gregory Friedman, M.D. is devoted to studying malignant brain tumors in hopes of developing new and improved immunotherapies to treat children with recurrent tumors. One such treatment has shown promising preliminary results, and the therapy involves an unexpected source: the
Rally Foundation for Childhood Cancer Research Announces $3 Million in Grant Awards
In the United States, cancer is the number one disease killer of children. Yet pediatric cancer isn’t exclusive to America; it’s a global epidemic that affects more than 300,000 children around the world.
New Developments in Osteosarcoma Therapies
In the United States, cancer is the number one disease killer of children. Yet pediatric cancer isn’t exclusive to America; it’s a global epidemic that affects more than 300,000 children around the world.
